Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 6/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24916011 | 0.90 | PBK (0.38) | CNR2GSK3B | |
| SCHEMBL24916356 | 0.87 | TLR9 (0.44) | — | |
| SCHEMBL24916002 | 0.86 | SMYD3 (0.43) | CNR2NPC1POLBRAB9A | |
| SCHEMBL24916196 | 0.86 | PFKFB3 (0.38) | CNR2GSK3BCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24915998 | 0.84 | SMYD3 (0.47) | CNR2RAB9AMEN1KMT2A | |
| SCHEMBL24916193 | 0.83 | CSF1R (0.38) | CNR2NPC1KMT2AGSK3B | |
| SCHEMBL24915997 | 0.83 | GPR52 (0.39) | MEN1KMT2A | |
| SCHEMBL24915849 | 0.82 | PLK1 (0.37) | NPC1POLBRAB9ACYP1A2CYP2D6 | |
| SCHEMBL24916013 | 0.82 | MAP4K4 (0.40) | MEN1KMT2A | |
| SCHEMBL24915532 | 0.81 | LMNA (0.48) | NPC1POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | VANDERBILT UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026466-A1 | WDR5 INHIBITORS AND MODULATORS | WDR5, WDR1, WDR3 | CNR2 3646/4885NPC1 1407/4885POLB 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.